Publication Name	World Journal of Orthopedics
Manuscript ID	1799
Country	Japan

Received	2013-01-07 09:49
Peer-Review Started	2013-01-07 17:01
To Make the First Decision	2013-02-21 21:51
Return for Revision	2013-02-27 10:19
Revised	2013-05-21 10:00
Second Decision	2013-06-19 12:53
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2013-06-20 00:50
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-09-16 10:41
Publish the Manuscript Online	2013-10-28 15:24

ISSN	2218-5836 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Review
Article Title	RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases
Manuscript Source	Invited Manuscript
All Author List	Hisataka Yasuda
Funding Agency and Grant Number
Corresponding Author	Hisataka Yasuda, PhD, Bioindustry Division, Oriental Yeast Co., Ltd., 3-6-10 Azusawa, Itabashi-ku, Tokyo 174-8505, Japan. yasuda.hisataka@nisshin.com
Key Words	Osteoclast; Osteoblast; Receptor activator of nuclear factor-B ligand; Denosumab; Receptor activator of nuclear factor-B; Osteoprotegerin
Core Tip	This review describes a success story from discovery of osteoprotegerin/receptor activator of nuclear factor-?B ligand (RANKL)/receptor activator of nuclear factor-?B (RANK) to clinical application of a fully human anti-RANKL monoclonal antibody to the treatment of osteoporosis and cancer-related bone disorders. RANKL is a key molecule for osteoclast differentiation and activation. Inhibition of RANKL activity with anti-RANKL antibody reduces osteoclastogenesis, resulting in inhibition of bone resorption. Three animal disease models of osteoporosis, hypercalcemia, and osteopetrosis by treating normal mice with soluble RANKL (sRANKL), adenovirus expressing sRANKL, and anti-mouse RANKL neutralizing antibody, respectively, can be established in 2-14 d and the establishment of these animal models could help accelerate research on bone metabolism.
Publish Date	2013-10-28 15:24
Citation	Yasuda H. RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases. World J Orthop 2013; 4(4): 207-217
URL	http://www.wjgnet.com/2218-5836/full/v4/i4/207.htm
DOI	http://dx.doi.org/10.5312/wjo.v4.i4.207

Full Article (PDF)	WJO-4-207.pdf
Manuscript File	1799-review.doc
Answering Reviewers	1799-Answering reviewers.doc
Copyright License Agreement	1799-Copyright assignment.pdf
Peer-review Report	1799-Peer review(s).pdf
Scientific Editor Work List	1799-Scientific editor work list.doc